Touyun Biotech (1332) Sets 27 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend

Bulletin Express

Mar 13

Touyun Biotech Group Limited (Stock Code: 1332) has scheduled a board meeting for Friday, 27 March 2026. According to the company’s announcement, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider a proposal for a final dividend.

The board currently consists of: • Executive Directors: Wang Liang (Chairman), Du Dong, Zhang Lele • Non-executive Directors: Chen Hui, Tian Yuze • Independent Non-executive Directors: Cheung Wing Ping, Ha Kee Choy Eugene, To Shing Chuen

The notice was issued in Hong Kong on 13 March 2026 and signed by Chairman Wang Liang.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1133304657"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133304657\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133304657?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133304657","market":"hk","top_or_hot":-1,"title":"Touyun Biotech (1332) Sets 27 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend","media":"Bulletin Express","content":"<p>Touyun Biotech Group Limited (Stock Code: 1332) has scheduled a board meeting for Friday, 27 March 2026. According to the company’s announcement, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider a proposal for a final dividend.</p>\n<p>The board currently consists of:\n• Executive Directors: Wang Liang (Chairman), Du Dong, Zhang Lele  \n• Non-executive Directors: Chen Hui, Tian Yuze  \n• Independent Non-executive Directors: Cheung Wing Ping, Ha Kee Choy Eugene, To Shing Chuen</p>\n<p>The notice was issued in Hong Kong on 13 March 2026 and signed by Chairman Wang Liang.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Touyun Biotech (1332) Sets 27 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTouyun Biotech (1332) Sets 27 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Touyun Biotech Group Limited (Stock Code: 1332) has scheduled a board meeting for Friday, 27 March 2026. According to the company’s announcement, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider a proposal for a final dividend.</p>\n<p>The board currently consists of:\n• Executive Directors: Wang Liang (Chairman), Du Dong, Zhang Lele  \n• Non-executive Directors: Chen Hui, Tian Yuze  \n• Independent Non-executive Directors: Cheung Wing Ping, Ha Kee Choy Eugene, To Shing Chuen</p>\n<p>The notice was issued in Hong Kong on 13 March 2026 and signed by Chairman Wang Liang.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01332","symbol_name":"透云生物","start_time":0,"source_url":"","article_id":"1133304657","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133304657","pubTimestamp":1773393651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Touyun Biotech Group Limited (Stock Code: 1332) has scheduled a board meeting for Friday, 27 March 2026. According to the company’s announcement, directors will review and approve the consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01332":"透云生物"},"translate_title":"透云生物(1332)定于2026年3月27日召开董事会批准2025财年业绩并讨论末期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01332":1},"content_text":"Touyun Biotech Group Limited (Stock Code: 1332) has scheduled a board meeting for Friday, 27 March 2026. According to the company’s announcement, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider a proposal for a final dividend.\nThe board currently consists of:\n• Executive Directors: Wang Liang (Chairman), Du Dong, Zhang Lele  \n• Non-executive Directors: Chen Hui, Tian Yuze  \n• Independent Non-executive Directors: Cheung Wing Ping, Ha Kee Choy Eugene, To Shing Chuen\nThe notice was issued in Hong Kong on 13 March 2026 and signed by Chairman Wang Liang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}